NasdaqGS:TNYABiotechs
How TN-301 Progress And Alnylam Deal At Tenaya Therapeutics (TNYA) Has Changed Its Investment Story
In early March 2026, Tenaya Therapeutics reported a narrower full-year 2025 net loss of US$90.6 million and highlighted new preclinical data for TN-301 in Duchenne muscular dystrophy alongside a research collaboration with Alnylam Pharmaceuticals on up to 15 cardiovascular gene targets that could yield as much as US$1.13 billion in milestones.
Together, these updates underscore how Tenaya is pairing emerging HDAC6 science in DMD and heart failure with a genetically guided partnership model...